US generic drug manufacturing push faces steep economic hurdles

The US government's campaign to reduce reliance on foreign-made pharmaceuticals by boosting domestic generic drug manufacturing is hitting a wall of economic and regulatory reality. While policymakers look to secure critical medicine supplies, the global drug trade's deep reliance on India illustrates why onshoring these low-cost treatments is proving extremely difficult.

At the heart of the issue is a stark cost imbalance. Generic medicines account for roughly nine out of ten prescriptions filled in the United States. Yet, the vast majority of these drugs, or the raw chemical ingredients needed to make them, are imported—primarily from India and China. Indian manufacturers, supported by low labour costs, government incentives, and decades of specialised infrastructure, produce these medicines at prices that American facilities simply cannot match.

Why the supply chain is hard to replicate

The challenge goes beyond simply pressing pills into tablets. The pharmaceutical supply chain is split into two parts: making the Active Pharmaceutical Ingredient (API)—the actual chemical that treats the illness—and formulating the final dose. Even India, which is often called the "pharmacy of the world," depends on China for about 70 per cent of its key starting materials and APIs. For the US to build a truly independent supply chain, it would have to replicate not just India’s formulation factories, but also the chemical manufacturing capabilities that India itself struggles to onshore.

Environmental and regulatory hurdles in the US further complicate the picture. Manufacturing APIs is a chemically intensive, highly polluting process. Establishing new chemical plants in the US requires complying with strict Environmental Protection Agency (EPA) regulations and lengthy permitting processes, which adds years and millions of dollars to setup costs. In contrast, Indian hubs like Hyderabad have created dedicated chemical zones designed to handle toxic waste at scale, although not without significant local environmental costs.

The market forces blocking domestic production

Moreover, the economics of the US generic market do not support high-cost domestic production. Group purchasing organisations (GPOs) in the US buy drugs in massive quantities and constantly squeeze manufacturers for the lowest possible price. Because generics are treated as commodities, buyers will almost always choose a cheaper Indian or Chinese import over a more expensive American-made alternative.

Under these conditions, private investment in US generic factories remains minimal, as there is no clear path to profitability. Without sustained government subsidies or a fundamental change in how generic drugs are priced and purchased, industry analysts argue that domestic manufacturing will remain limited to niche products. While national security and supply chain resilience remain top priorities in Washington, for the foreseeable future, American healthcare will continue to rely on the factories of India to keep its medicine cabinets stocked.